Free assessment, 100% online
Complete your online assessment to begin your Riovie journey.
Take AssessmentA once-per-week GLP-1 weight management injection.
| Option | 1 Month | 3 Month | Per month |
|---|---|---|---|
| Tirzepatide | $209 | $585 | $195 |
| Semaglutide | $149 | $345 | $115 |
No added formulation fee.
Common side effects of GLP-1 injections may include nausea, diarrhea, and vomiting. To help your body adjust, eligible patients may add-on a fast-acting anti-nausea medication.
Complete your online assessment to begin your Riovie journey.
Take AssessmentA licensed provider reviews your information and determines whether treatment is appropriate.
Find out if I am eligibleIf prescribed, your medication is delivered to your door with shipping included.
Get StartedIt’s part of the wrapped care included when you begin treatment with a Riovie provider.
Licensed provider eligibility review.
Get Started
Secure portal messaging with Riovie Support.
Get StartedPrescribed by licensed clinicians. Shipped from licensed U.S. pharmacies.
Elsewhere, B12 or glycine combinations can carry premium pricing. Riovie keeps eligible premium and base GLP-1 formulations at the same low plan price.*
Base GLP-1 is also available: semaglutide and tirzepatide at these same plan prices.
*One-month plan prices shown; the three-month plan costs less per month. If clinically appropriate, selected, and prescribed, available formulations may include base semaglutide or tirzepatide, or either medication compounded with B12 or glycine. Base or premium formulation choice does not change the plan price. Competitor pricing and formulations vary. Vial imagery is stylized and does not reflect the actual label or vial size. Compounded drugs are not FDA-approved or evaluated for safety, effectiveness, or quality.
Your licensed provider will determine the appropriate medication and formulation based on your health history, clinical eligibility, and availability.
Stylized vial for marketing purposes only; image does not reflect the actual label or size of prescription vial. Compounded products are not approved nor evaluated for safety, efficacy, or quality by the FDA.
Prescription required; treatment is subject to your provider’s evaluation and approval. Taxes may apply where required. See Important Safety Information for full pricing and promotional terms.
Refer to the following important safety details for information on intended use, potential side effects and risks, considerations for specific groups, and possible drug interactions linked to the prescription treatments mentioned.
Riovie encourages users to promptly report any side effects or adverse reactions to a licensed healthcare provider and the pharmacy that dispensed the medication. To report suspected reactions to these medications, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
For emergencies, call 911 or go to your nearest emergency department.
All advertisements from riovie.com are paid for by Riovie and are intended to market Riovie’s services. Some advertisements may feature paid actors or dramatizations. When real Riovie customers or endorsements are included, this will be clearly disclosed. Individual results may vary, and specific outcomes are not guaranteed.
Riovie connects users with licensed healthcare providers for evaluations regarding the suitability of the treatments advertised. It may also assist with prescription coordination through an external pharmacy network.
Riovie acts as a managed services provider and does not offer medical advice, fill prescriptions, or function as a licensed healthcare facility or pharmacy. Instead, it provides technology and administrative support to enable medical consultations and prescription logistics. For further details, see Riovie’s Terms of Service.
Occasionally, the website may present promotional pricing or special introductory offers. These promotions are valid for 24 hours after they are removed from the website.
The claim “same price at every dose” is subject to the following:
Prescription drugs require evaluation and approval by a qualified healthcare provider, and issuance is solely at the provider’s discretion. Access to treatment plans and medications is not assured.
Prescriptions issued through Riovie may be filled by licensed pharmacies within its affiliated network.
All prescription medications involve potential risks. Please review all associated safety details and consult your provider for personalized advice.
In certain situations, healthcare providers may prescribe compounded medications, which are custom-prepared by licensed compounding pharmacies based in the U.S. These medications are not FDA-approved for safety or effectiveness but may be used when alternatives are not available or appropriate.
Riovie helps facilitate both FDA-approved and compounded medication fulfillment via its partner pharmacy network. These formulations are personalized to meet individual patient requirements and may differ from commercial products.
Mounjaro® and Zepbound® are registered trademarks owned by Eli Lilly and Company. Riovie is not affiliated with or endorsed by the manufacturers of any brand-name medications. For further information, visit Eli Lilly’s official website.
Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Riovie is not affiliated with or endorsed by Novo Nordisk A/S, the manufacturer of these medications. For further information, visit Novo Nordisk’s official website.
For any questions about Riovie’s services or advertising content, please reach out to support@riovie.com.
Please be aware that compounded drugs are not FDA-approved and do not undergo clinical studies to evaluate for safety and efficacy. Your healthcare provider may prescribe compounded semaglutide based on your medical consultation.
Semaglutide is a GLP-1 receptor agonist used for chronic weight management alongside a reduced-calorie diet and increased physical activity for people with a BMI of:
Do not use semaglutide if:
Inform your healthcare provider if you:
Serious risks include:
Common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, headache, tiredness, indigestion, bloating, belching, heartburn, and upper respiratory symptoms.
Administration: Inject subcutaneously once weekly on the same day in the stomach, thigh, or upper arm, with or without food.
Reporting side effects: Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Compounded tirzepatide is not FDA-approved but may be prescribed legally based on your provider’s assessment.
Tirzepatide is a GIP and GLP-1 receptor agonist used for chronic weight management with lifestyle changes in adults with a BMI of:
Do not use tirzepatide if:
Inform your provider if you:
Serious risks include:
Common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss, and heartburn.
Administration: Inject subcutaneously once weekly on the same day in the stomach, thigh, or upper arm.
Reporting side effects: Contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This document is not comprehensive. Always speak with a licensed healthcare provider for personalized medical advice.